BioMimetic Therapeutics' Study to Receive Award for Outstanding Publication from American Academy of Periodontology
Franklin, Tenn. – October 30, 2007 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that for the second consecutive year a study designed and sponsored by the Company has been honored with the prestigious R. Earl Robinson Regeneration Award from the American Academy of Periodontology for the most outstanding scientific publication in the field of regenerative medicine and periodontics. The paper, which described the use of new composite endpoints to assess therapeutic outcomes in periodontal clinical trials, was authored by three BMTI executives and two other scientific collaborators.
The publication demonstrated that new composite endpoints combining clinical and radiological measurements may be used to accurately assess regenerative outcomes concurrently on both bone and adjacent soft tissues. The R. Earl Robinson Regeneration Award is presented to the author(s) of the peer-reviewed published paper that has contributed most to the knowledge of regenerative medicine in periodontology in a given calendar year. The Award was presented to Dr. Samuel Lynch, BMTI president and CEO, Mr. William G. Beasley, and Dr. Leslie A. Wisner-Lynch, BMTI's Director of Clinical Affairs and Director of Applied Research, respectively, and their co-authors, Drs. Philip T. Lavin and Robert J. Genco, at the 93rd Annual Meeting of the American Academy of Periodontology (AAP) in Washington, DC, on Saturday, October 27, 2007.
"I am honored and humbled that the Academy has chosen one of our clinical research papers to receive this award for the second year in a row," said Dr. Lynch. "Our entire team at BMTI strives to achieve the highest, scientific and clinical research standards and to receive this award by a preeminent organization such as the AAP twice is a wonderful recognition of the world-class standards our team achieves." In the 18 year history of the R. Earl Robinson Regeneration Award, no research team has received the award in two consecutive years.
In the composite analyses, treatment with BMTI's lead product, GEM 21S, which is a combination of rhPDGF-BB (recombinant human platelet-derived growth factor BB) and an osteoconductive bone matrix, beta-tricalcuim phosphate (B-TCP), resulted in significantly better outcomes, compared to the active control, B-TCP, alone. GEM 21S is marketed in the dental field by the Osteohealth Company, a division of Luitpold Pharmaceuticals, a wholly owned subsidiary of Diiachi Sankyo, Inc. A similar product candidate containing rhPDGF-BB and B-TCP is in pivotal (phase III) clinical trials in orthopedics as a substitute for autologous bone grafts in foot and ankle fusion procedures. BMTI plans to market that product itself.
About BioMimetic Therapeutics
BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, periodontal, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S®, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of its platform technology in this indication. Additionally, the Company has clinical trials ongoing with its product candidates GEM OS®1 and GEM OS®2 in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the arm. The Company's product and lead product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration.
Forward-looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of BioMimetic. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. There are many important factors that could cause actual results to differ materially from those indicated in the forward-looking statements. BioMimetic's actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with the marketing of BioMimetic's product and product candidates, unproven preclinical and clinical development activities, regulatory oversight and approval, and other risks detailed in the company's filings with the Securities and Exchange Commission. Except as required by law, BioMimetic undertakes no responsibility for updating the information contained in this press release beyond the published date, whether as a result of new information, future events or otherwise, or for changes made to this document by wire services or Internet services.
For further information, visit www.biomimetics.com or contact Kearstin Patterson, corporate communications, at 615-236-4419.
Back to Headlines |
